Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris

European Journal of Pharmacology

Volumn 560, Issue 1, 2007, Pages 49-55

  Liberts, Elizabeth A ^a   Willoughby, Scott R ^a   Kennedy, Jennifer A ^a   Horowitz, John D ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Nitroglycerin; Perhexiline; Superoxide release

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PERHEXILINE; SUPEROXIDE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG INFUSION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOCYTE FUNCTION; MALE; NEUTROPHIL; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ANGINA PECTORIS; ARTERIES; CARDIOVASCULAR PHYSIOLOGY; DRUG INTERACTIONS; FEMALE; HUMANS; LUMINESCENCE; MALE; MANOMETRY; MIDDLE AGED; NEUTROPHILS; NITROGLYCERIN; PERHEXILINE; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; SUPEROXIDES; VASODILATOR AGENTS;

EID: 33847246339     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.001     Document Type: Article

References (42)

1. Arstall M.A., Yang J., Stafford I., Betts W.H., and Horowitz J.D. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 92 (1995) 2855-2862
2. Barry W.H., Horowitz J.D., and Smith T.W. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br. J. Pharmacol. 85 (1985) 51-59
3. Bauersachs J., Bouloumie A., Mulsch A., Wiemer G., Fleming I., and Busse R. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc. Res. 37 (1998) 772-779
4. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347 (2002) 5-12
5. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., and Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
6. Chirkov Y.Y., Holmes A.S., Chirkova L.P., and Horowitz J.D. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 100 (1999) 129-134
7. Chirkov Y.Y., Holmes A.S., Martelli J.D., and Horowitz J.D. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am. J. Cardiol. 93 (2004) 1438-1440
8. Cole P.L., Beamer A.D., McGowan N., Cantillon C.O., Benfell K., Kelly R.A., Hartley L.H., Smith T.W., and Antman E.M. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81 (1990) 1260-1270
9. Ellis G.R., Anderson R.A., Lang D., Blackman D.J., Morris R.H., Morris-Thurgood J., McDowell I.F., Jackson S.K., Lewis M.J., and Frenneaux M.P. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J. Am. Coll. Cardiol. 36 (2000) 1474-1482
10. Fleckenstein-Grun G., Fleckenstein A., Byron Y., and Kim K. Mechanisms of action of calcium antagonists in the treatment of CAD with special reference to perhexiline maleate. Perhexiline Maleate. Proceedings of a symposium (1978), Exerpta Medica, Amsterdam 1
11. Horowitz J.D., Sia S.T., Macdonald P.S., Goble A.J., and Louis W.J. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int. J. Cardiol. 13 (1986) 219-229
12. Iqbal M., Okazaki Y., Sharma S.D., and Okada S. Nitroglycerin, a nitric oxide generator attenuates ferric nitrilotriacetate-induced renal oxidative stress, hyperproliferative response and necrosis in ddY mice. Biochim. Biophys. Acta 1623 (2003) 98-108
13. ISIS-4 investigators. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345 (1995) 669-685
14. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., and Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
15. Jeffrey F.M., Alvarez L., Diczku V., Sherry A.D., and Malloy C.R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol. 25 (1995) 469-472
16. Jin J.S., and D'Alecy L.G. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J. Cardiovasc. Pharmacol. 28 (1996) 439-446
17. John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., and Schmieder R.E. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J. Am. Coll. Cardiol. 37 (2001) 1351-1358
18. Kelly E.A., Ahmed R.M., and Horowitz J.D. Withdrawal of intravenous glyceryl trinitrate: absence of rebound phenomena with transition to oral isosorbide dinitrate. Clin. Exp. Pharmacol. Physiol. 32 (2005) 269-272
19. Kennedy J.A., Kiosoglous A.J., Murphy G.A., Pelle M.A., and Horowitz J.D. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J. Cardiovasc. Pharmacol. 36 (2000) 794-801
20. Kennedy J.A., Beck-Oldach K., McFadden-Lewis K., Murphy G.A., Wong Y.W., Zhang Y., and Horowitz J.D. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur. J. Pharmacol. 531 (2006) 13-19
21. Klaus W., and Guttler K. Functional effects of perhexiline maleate on the isolated myocardium. Perhexiline Maleate. Proceedings of a symposium (1978), Exerpta Medica, Amsterdam 23
22. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., and Harrison D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95 (1997) 588-593
23. Lee L., Horowitz J.D., and Frenneaux M.P. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J. 25 (2004) 634-641
24. Lee L., Campbell R., Scheuermann-Freestone M., Taylor R., Gunaruwan P., Williams L., Ashrafian H., Horowitz J., Fraser A.G., Clarke K., and Frenneaux M.P. Metabolic modulation with perhexiline in chronic heart failure: a randomised controlled trial on short term use of a novel treatment. Circulation 112 (2005) 3280-3288
25. Mizumura T., Nithipatikom K., and Gross G.J. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc. Res. 29 (1995) 482-489
26. Munzel T., Kurz S., Rajagopalan S., Thoenes M., Berrington W.R., Thompson J.A., Freeman J.A., and Harrison D.G. Hydralazine prevents nitroglycerine tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 98 (1996) 1465-1470
27. Naruko T., Ueda M., Haze K., van der Wal A.C., van der Loos C.M., Itoh A., Komatsu R., Ikura Y., Ogami M., Shimada Y., Ehara S., Yoshiyama M., Takeuchi K., Yoshikawa J., and Becker A.E. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 (2002) 2894-2900
28. Philpott A., Chandy S., Morris R., and Horowitz J.D. Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes. Intern. Med. J. 34 (2004) 361-363
29. Pieper G.M., and Gross G.J. Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc. Drugs Ther. 6 (1992) 225-232
30. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
31. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
32. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., Jachmann N., Post F., Peetz D., Bickel C., Cambien F., Tiret L., and Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97 (2005) e53-e59
33. Stewart S., Voss D.W., Northey D.L., and Horowitz J.D. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther. Drug Monit. 18 (1996) 635-639
34. Sugano R., Matsuoka H., Haramaki N., Umei H., Murase E., Fukami K., Iida S., Ikeda H., and Imaizumi T. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1262-1267
35. Sydow K., and Munzel T. ADMA and oxidative stress. Atheroscler. Suppl. 4 (2003) 41-51
36. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., Taylor M., Adams K., Sabolinski M., Worcel M., and Cohn J.N. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351 (2004) 2049-2057
37. van der Wal A.C., Becker A.E., van der Loos C.M., and Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
38. Vlachopoulos C., Hirata K., and O'Rourke M.F. Pressure-altering agents affect central aortic pressures more than is apparent from upper limb measurements in hypertensive patients: the role of arterial wave reflections. Hypertension 38 (2001) 1456-1460
39. Wang J.P., Chang L.C., Raung S.L., Hsu M.F., Huang L.J., and Kuo S.C. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and-independent mechanisms. Biochem. Pharmacol. 63 (2002) 577-585
40. Watanabe H., Kakihana M., Ohtsuka S., and Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J. Am. Coll. Cardiol. 31 (1998) 1323-1329
41. Willoughby S.R., Stewart S., Chirkov Y.Y., Kennedy J.A., Holmes A.S., and Horowitz J.D. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur. Heart J. 23 (2002) 1946-1954
42. Willoughby S.R., Stewart S., Holmes A.S., Chirkov Y.Y., and Horowitz J.D. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2661-2666